A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY,SAFETY AND TOLERABILITY OF MEDI3506 IN PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC BRONCHITIS (FRONTIER 4)

Intervention/treatment:
MEDI3506
Medical condition:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Protocol code:
D9180C00002
Control number:
243922
Status:
Closed
Approved:
October 13, 2020
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT04631016
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Clinical Lead
Organization
AstraZeneca Clinical Study Information Center
Phone:
+1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Newfoundland and Labrador

Research Site
St. John's, Newfoundland and Labrador, A1B 3V6

Ontario

Research Site
Ajax, Ontario, L1S 2J5

Quebec

Research Site
Québec, Quebec, G1G 3Y8
Research Site
Québec, Quebec, G2J 0C4
Research Site
Sherbrooke, Quebec, J1L 0H8
Research Site
Trois-Rivières, Quebec, G8T 7A1

Results

See the results from the trial NCT04631016. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?